Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

0.94USD
23 Apr 2018
Change (% chg)

$0.01 (+1.08%)
Prev Close
$0.93
Open
$0.95
Day's High
$0.95
Day's Low
$0.94
Volume
13,442
Avg. Vol
139,376
52-wk High
$2.65
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)

Overall

Beta: -0.57
Market Cap(Mil.): $17.09
Shares Outstanding(Mil.): 10.75
Dividend: --
Yield (%): --

Financials

  VTGN.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.36 -- --
ROI: -245.77 14.84 14.38
ROE: -415.24 16.34 16.07

BRIEF-VistaGen Therapeutics Reports Qtrly Loss Per Share $‍0.25​

* VISTAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS

12 Feb 2018

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​

* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER​ Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder

* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

03 Jan 2018

BRIEF-Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13

* REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC : AS OF DEC 13 - SEC FILING Source text: (http://bit.ly/2CNm098) Further company coverage:

20 Dec 2017

BRIEF-Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics

* SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC AS OF DEC 11 - SEC FILING Source text: (http://bit.ly/2ksLZuU) Further company coverage:

14 Dec 2017

BRIEF-Vistagen Therapeutics posts Q2 loss of $0.53 per share

* Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update

09 Nov 2017

BRIEF-Vistagen Therapeutics receives European patent for AV-101 for treatment of depression

* Vistagen Therapeutics receives European patent for AV-101 for treatment of depression Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder

* Vistagen announces fda authorization to initiate phase 2 study of av-101 for major depressive disorder Source text for Eikon: Further company coverage:

26 Oct 2017

Competitors

Earnings vs. Estimates